Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Q/C TECHNOLOGIES, INC.AKER · Entity 7735 | Director · Chief Executive Officer | October 17, 2017 | April 11, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Q/C TECHNOLOGIES, INC.
Report date October 17, 2017 · Filed April 11, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,000 |
Reported balance
After 2017-10-17 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-10-17 · Grant · Acquired 150,000 · Balance 180,000 F1: On October 17, 2017, the Board of Directors of Akers Biosciences, Inc. approved the issuance of 150,000 restricted shares of common stock to the reporting person pursuant to the Akers Biosciences, Inc. 2017 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 17, 2017, the Board of Directors of Akers Biosciences, Inc. approved the issuance of 150,000 restricted shares of common stock to the reporting person pursuant to the Akers Biosciences, Inc. 2017 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 17, 2017 Filed Oct 24, 2017 20:50 UTC | Q/C TECHNOLOGIES, INC. AKER · Entity 7735 | GiftCommon Stock | 150,000 | $0.88 | $132,000.00 |
DisclosureSEC source: 0001493152-17-011992 · form-4.xml · nonDerivative · entry 1 Gormally John J · CIK 0001661118 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 F1 · shares: On October 17, 2017, the Board of Directors of Akers Biosciences, Inc. approved the issuance of 150,000 restricted shares of common stock to the reporting person pursuant to the Akers Biosciences, Inc. 2017 Equity Incentive Plan. Read SEC document |
| October 17, 2017 Filed Apr 11, 2018 00:42 UTC Amendment | Q/C TECHNOLOGIES, INC. AKER · Entity 7735 | GrantCommon Stock | 150,000 | $0.88 | $132,000.00 |
DisclosureSEC source: 0001493152-18-005018 · form4a.xml · nonDerivative · entry 1 Gormally John J · CIK 0001661118 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 F1 · shares: On October 17, 2017, the Board of Directors of Akers Biosciences, Inc. approved the issuance of 150,000 restricted shares of common stock to the reporting person pursuant to the Akers Biosciences, Inc. 2017 Equity Incentive Plan. Read SEC document |
| June 08, 2016 Filed Apr 11, 2018 00:40 UTC Amendment | Q/C TECHNOLOGIES, INC. AKER · Entity 7735 | GrantCommon Stock | 27,500 | $1.99 | $54,725.00 |
DisclosureSEC source: 0001493152-18-005016 · form4a.xml · nonDerivative · entry 1 Gormally John J · CIK 0001661118 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: On June 8, 2016 Mr. Gormally was issued 27,500 shares of common stock (the "Shares") under the Company's 2013 Incentive Stock and Award Plan, as amended. Pursuant to the Restricted Stock Agreement between Mr. Gormally and the Company governing the issuance of the Shares, 9,167 of the Shares vested on June 8, 2016, 9,167 of the Shares will vest on March 1, 2017, and 9,166 of the Shares will vest on March 1, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.